Literature DB >> 6173424

Anti-RNP monoclonal antibodies derived from a mouse strain with lupus-like autoimmunity.

P B Billings, R W Allen, F C Jensen, S O Hoch.   

Abstract

systemic lupus erythematosus (SLE) and related rheumatic and connective-tissue diseases are often associated with the production of antibodies directed against a variety of specific cellular components. Recent evidence indicates that two such autoantigens, the Sm and RNP antigens recognized by SLE sera, exist in small ribonucleoprotein complexes found in the nuclei of higher eukaryotes. Studies of the structure and function of these autoantigenic particles with human sera used as probes have been limited because of the multiplicity of autoantibodies often found in an individual serum. Through this communication, we report that MRL/Mp-+/+ (MRL/n) mice, which spontaneously develop a disease exhibiting many of the characteristics of human SLE, possess anti-RNP antibodies in addition to anti-Sm and anti-DNA as previously reported. Spleen cells from one such autoimmune mouse were used to produce a stable hybridoma secreting antibodies that react simultaneously with a protein of Mr 40,000 and a doublet of approximately 70,000, a pattern of reactivity identical to and characteristic of human SLE anti-RNP autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173424

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

Review 1.  Mapping of epitopes recognized by anti-(U1)RNP autoantibodies.

Authors:  H H Guldner
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  U1 small nuclear ribonucleoprotein particle-specific proteins interact with the first and second stem-loops of U1 RNA, with the A protein binding directly to the RNA independently of the 70K and Sm proteins.

Authors:  J R Patton; W Habets; W J van Venrooij; T Pederson
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

3.  Multiple properties of the splicing repressor SRp38 distinguish it from typical SR proteins.

Authors:  Chanseok Shin; Frida E Kleiman; James L Manley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  Nuclear matrins: identification of the major nuclear matrix proteins.

Authors:  H Nakayasu; R Berezney
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Immunoreactivity between a monoclonal lupus autoantibody and the arginine/aspartic acid repeats within the U1-snRNP 70K autoantigen is conformationally restricted.

Authors:  S Pelsue; P F Agris
Journal:  J Protein Chem       Date:  1994-05

6.  Characterization of an anti-RNA recombinant autoantibody fragment (scFv) isolated from a phage display library and detailed analysis of its binding site on U1 snRNA.

Authors:  S W Teunissen; M H Stassen; G J Pruijn; W J van Venrooij; R M Hoet
Journal:  RNA       Date:  1998-09       Impact factor: 4.942

7.  WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif.

Authors:  M T Bedford; R Reed; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein.

Authors:  M Satoh; J J Langdon; K J Hamilton; H B Richards; D Panka; R A Eisenberg; W H Reeves
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.

Authors:  Hideo Yoshida; Minoru Satoh; Krista M Behney; Chee-Gun Lee; Hanno B Richards; Victoria M Shaheen; Jun-Qi Yang; Ram R Singh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2002-08

10.  Individual variation of anti-Sm autoantibodies in the MRL/MP-lpr/lpr mouse: age-related increase in diversity.

Authors:  D G Williams; F M Brennan; M R Stocks; R N Maini
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.